var data={"title":"Black widow spider (Latrodectus mactans) antivenom: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Black widow spider (Latrodectus mactans) antivenom: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5655?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=black-widow-spider-latrodectus-mactans-antivenom-drug-information\" class=\"drug drug_general\">see &quot;Black widow spider (Latrodectus mactans) antivenom: Drug information&quot;</a> and <a href=\"topic.htm?path=black-widow-spider-latrodectus-mactans-antivenom-patient-drug-information\" class=\"drug drug_patient\">see &quot;Black widow spider (Latrodectus mactans) antivenom: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045279\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antivenin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045274\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=black-widow-spider-latrodectus-mactans-antivenom-drug-information\" class=\"drug drug_general\">see &quot;Black widow spider (Latrodectus mactans) antivenom: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> The initial dose of antivenin should be administered as soon as possible for prompt relief of symptoms. Delayed antivenin administration may still be effective in treating patients with prolonged or refractory symptoms resulting from black widow spider bites; a case report describes use of antivenin administration up to 90 hours after bite (O&rsquo;Malley 1999); however, delayed administration may decrease effectiveness (Edberg 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>Sensitivity testing:</b></i> Infants, Children, and Adolescents: Skin testing may identify allergic individuals, but the lack of an initial reaction does not eliminate the possibility of a hypersensitivity reaction; therefore, always be prepared to treat an unanticipated hypersensitivity reaction. Intradermal skin test or conjunctival test may be performed prior to antivenin administration:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Skin test: Intradermal: Up to 0.02 mL of a 1:10 dilution of normal horse serum (provided in kit) in NS; evaluate after 10 minutes against a control test (intradermal injection of 0.02 mL NS). <b>Note:</b> Positive reaction consists of an urticarial wheal surrounded by a zone of erythema.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conjunctival test: Instill 1 drop of 1:100 dilution of normal horse serum into conjunctival sac; a positive reaction is indicated by itching of the eye and/or reddening of conjunctiva, usually occurring within 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>Desensitization:</b></i> Infants, Children, and Adolescents: In separate vials or syringes, prepare 1:10 and 1:100 dilutions of antivenin in NS:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">SubQ: Inject 0.1 mL, followed by 0.2 mL and 0.5 mL of a 1:100 dilution at 15- to 30-minute intervals. During desensitization procedure, proceed with the next dose only if a reaction has <b>not</b> occurred following the previous dose. Repeat procedure with a 1:10 dilution of antivenin; and then with undiluted antivenin. If no reaction has occurred following administration of 0.5 mL of undiluted antivenin, continue the dose at 15-minute intervals until the entire dose has been administered.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If a reaction occurs, apply a tourniquet proximal to the injection site and administer epinephrine (1 mg/mL) SubQ or IV proximal to the tourniquet or into another extremity. Wait at least 30 minutes, then administer another antivenin injection at the previous dilution which did not evoke a reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Latrodectus mactans</i> (black widow spider) envenomation; other <i>Latrodectus</i> spp envenomation</b> (Clark 2001): Infants, Children, and Adolescents: Limited data in infants (Monte 2011; Nordt 2012): Limited data available for some types of envenomations. <b>Note:</b> If a positive reaction to a skin or conjunctival test occurs and antivenin therapy is necessary, pretreat the patient with intravenous diphenhydramine and an H<sub>2</sub>-blocker while having a syringe of epinephrine (1 mg/mL) at the bedside:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;12 years: IM; IV (preferred): One vial (2.5 mL); a second dose may be needed in some cases; more than 1 to 2 vials are rarely required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: IM, IV: One vial (2.5 mL); a second dose may be needed in some cases; more than 1 to 2 vials are rarely required</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: The initial dose of antivenin should be administered as soon as possible for prompt relief of symptoms. Delayed antivenin administration may still be effective in treating patients with prolonged or refractory symptoms resulting from black widow spider bites; case report of antivenin administration up to 90 hours after bite (O&rsquo;Malley 1999); however, delayed administration may decrease effectiveness (Edberg 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sensitivity testing:</b> Skin testing may identify allergic individuals, but the lack of an initial reaction does not eliminate the possibility of a hypersensitivity reaction; therefore, always be prepared to treat an unanticipated hypersensitivity reaction. Intradermal skin test or conjunctival test may be performed prior to antivenin administration:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Skin test: Intradermal: Up to 0.02 mL of a 1:10 dilution of normal horse serum in NS; evaluate after 10 minutes against a control test (intradermal injection of NS). <b>Note:</b> A positive reaction is an urticarial wheal surrounded by a zone of erythema.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conjunctival test: Ophthalmic: Instill 1 drop of a 1:10 dilution of normal horse serum in NS into the conjunctival sac; <b>Note:</b> Itching of the eye and/or reddening of conjunctiva indicates a positive reaction, usually occurring within 10 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Desensitization:</b> In separate vials or syringes, prepare 1:10 and 1:100 dilutions of antivenin in NS.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">SubQ: Inject 0.1 mL, 0.2 mL, and 0.5 mL of the 1:100 dilution at 15- to 30-minute intervals. During this procedure, proceed with the next dose only if a reaction has <b>not</b> occurred following the previous dose. Repeat procedure using the 1:10 dilution and then undiluted antivenin. If no reaction has occurred following administration of 0.5 mL of undiluted antivenin, continue the dose at 15-minute intervals until the entire dose has been administered.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If a reaction occurs, apply a tourniquet proximal to the injection site and administer epinephrine (1 mg/mL) SubQ or IV proximal to the tourniquet or into another extremity. Wait at least 30 minutes; then administer another antivenin injection at the previous dilution which did not evoke a reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Envenomation due to <i>Latrodectus mactans</i> (black widow spider); envenomation due to other <i>Latrodectus</i> spp (Clark 2001; Isbister 2003):</b> Limited data available for some types of envenomations. <b>Note</b>: If a positive reaction to a skin or conjunctival test occurs and antivenin therapy is necessary, pretreat the patient with intravenous diphenhydramine and an H<sub>2</sub>-blocker while having a syringe of epinephrine (1 mg/mL) at the bedside: IM, IV: One vial (2.5 mL); a second dose may be needed in some cases; more than 1 to 2 vials are rarely required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24673690\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 6000 Antivenin units</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136014\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045282\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antivenin for treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Administer antivenin into the anterolateral thigh. Apply tourniquet proximal to the injection site if an adverse reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Infuse antivenin over 15 to 30 minutes (Clark 2001). IV administration preferred in severe cases, with shock, or in children &lt;12 years of age. There appears to be no clinical difference in efficacy between the IM and IV route of administration (Isbister 2008). If an immediate hypersensitivity reaction occurs, immediately interrupt antivenin infusion and provide appropriate supportive therapy. If administration of antivenin can be resumed after control of the reaction, reinitiate at a slower infusion rate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Horse serum for sensitivity testing:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intradermal: Inject the horse serum test solution into (not under) the skin; evaluate after 10 minutes against a control test (intradermal injection of NS).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Instill the horse serum test solution (appropriate dilution: Pediatric: 1:100; Adult: 1:10) into the conjunctival sac; a positive reaction, if present, will generally occur within 10 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antivenin for desensitization: SubQ: Administer the antivenin solution (See Dosing-Usual for appropriate concentration) via subQ injection. Allow 15 to 30 minutes between injections; proceed with the next dose only if a reaction has <b>NOT</b> occurred following the previous dose. If a reaction occurs, apply a tourniquet proximal to the injection site and administer epinephrine (1 mg/mL concentration) SubQ or IV proximal to the tourniquet or into another extremity. Wait at least 30 minutes prior to continuing the desensitization procedure. If no reaction occurred after administration of 0.5 mL of antivenin (undiluted), then may consider administering dose at 15 minute intervals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136035\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Refrigerate at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Do not freeze.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045281\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of patients with symptoms (eg, cramping, intractable pain, weaknesss, tremor, restless, anxious, convulsions, delirium, cold skin) refractory to supportive measures due to <i>Latrodectus mactans</i> (black widow spider) envenomation (FDA approved in children and adults); has also been used for treatment of patients with symptoms (eg, cramping, intractable pain, hypertension) refractory to supportive measures due to other <i>Latrodectus</i> spp (including <i>L. bishopi</i>, <i>L. geometricus</i>, <i>L. hesperus</i>, and <i>L. variolus</i>) envenomation; <b>Note:</b> The morbidity associated with <i>Latrodectus</i> envenomation is high, but mortality is low; therefore, the antivenin should not be used unless necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136053\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash (rare; associated with hypersensitivity reaction)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction, serum sickness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Muscle cramps </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136018\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergic reactions: May be less frequent than described in initial studies (Clark, 2001; Offerman, 2011). One retrospective study reviewed 163 cases of black widow spider envenomation; 58 patients received antivenin therapy and only 1 case of anaphylaxis occurred (Clark, 1992). The risk of reaction appears to be greatest with bolus administration of undiluted antivenin (Clark, 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Delayed serum sickness: Delayed serum sickness, albeit uncommon, may occur 1 to 2 weeks following administration, especially when large doses are used (Clark, 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Horse serum hypersensitivity: Carefully review allergies and history of exposure to products containing horse serum. History of atopic sensitivity to horses may increase the risk of immediate sensitivity reactions. Use with caution in patients with asthma, hay fever, or urticaria; fatal anaphylaxis has been reported in patients with a history of asthma. All patients require close monitoring in a setting where resuscitation can be performed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly patients: Due to an increased risk for complications of envenomation, the administration of antivenin may be the preferred initial therapy in patients &gt;60 years of age. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thimerosal: Some products may contain thimerosal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Desensitization: A desensitization protocol is available if sensitivity tests are mildly or questionably positive to reduce risk of immediate severe hypersensitivity reaction. According to the manufacturer, desensitization should be performed when antivenin administration would be lifesaving; however, the risk of anaphylaxis should be weighed against the risks associated with delayed antivenin administration (Rojnuckarin, 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin/conjunctival test: A skin or conjunctival test may be performed prior to use; however, the utility of skin and conjunctival tests to accurately identify patients at risk of early (anaphylactic) or late (serum sickness) hypersensitivity reactions to horse-derived antivenins has been questioned (WHO, 2005). Normal horse serum (1:10 dilution) is included for sensitivity testing. The absence of a skin or conjunctival hypersensitivity reaction does not exclude the possibility of anaphylaxis or hypersensitivity following antivenin administration. The false-negative rate for skin testing is 10% with similar agents. Conversely, hypersensitivity is not an absolute contraindication in a significantly envenomated patient.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298765\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6218053\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12889&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136022\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136033\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Use during pregnancy (second and third trimester) has been described in case reports; all patients delivered healthy infants (Handel, 1994; Russell, 1979; Sherman, 2000). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey, 2003). Treatment of a pregnant patient with antivenom should be considered early in the course of an envenomation and in patients experiencing local, regional, or systemic effects refractory to opioids and/or benzodiazepines (Brown, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045278\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Vital signs; hypersensitivity reactions; serum sickness (for 2 to 3 weeks following administration); worsening of symptoms due to envenomation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136017\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Neutralizes the venom of <i>Latrodectus mactans</i> (black widow spiders), but may also be effective following envenomation by other <i>Latrodectus</i> species (including <i>L. bishopi, L. geometricus, L. hesperus,</i> and <i>L. variolus</i>) (Clark, 2001; Isbister, 2003). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10180464\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">Onset of action: Within 30 minutes; symptoms of envenomation usually subside after 1-3 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045286\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">The venom of the black widow spider is a neurotoxin that causes release of a presynaptic neurotransmitter. Within 1 hour of the bite, the clinical effects of black widow spider envenomation (BWSE) include sharp pain, muscle spasm, weakness, tremor, severe abdominal pain with rigidity, hypertension, respiratory distress, diaphoresis, and facial swelling. Priapism has been reported in pediatric patients following BWSE (Hoover 2004; Quan 2009).</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Antivenin (<i>Latrodectus mactans</i>) (black widow spider antivenin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown SA1, Seifert SA, Rayburn WF. Management of envenomations during pregnancy. <i>Clin Toxicol (Phila)</i>. 2013;51(1):3-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/23298218/pubmed\" target=\"_blank\" id=\"23298218\">23298218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark RF, &quot;The Safety and Efficacy of Antivenin <i>Latrodectus mactans</i>,&quot; <i>J Toxicol Clin Toxicol</i>, 2001, 39(2):125-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/11407497/pubmed\" target=\"_blank\" id=\"11407497\">11407497</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark RF, Wethern-Kestner S, Vance MV, et al, &quot;Clinical Presentation and Treatment of Black Widow Spider Envenomation: A Review of 163 Cases,&quot;<i> Ann Emerg Med</i>, 1992, 21(7):782-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/1351707/pubmed\" target=\"_blank\" id=\"1351707\">1351707</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diaz JH, &quot;The Global Epidemiology, Syndromic Classification, Management, and Prevention of Spider Bites,&quot; <i>Am J Trop Med Hyg</i>, 2004, 71(2):239-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/15306718/pubmed\" target=\"_blank\" id=\"15306718\">15306718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edberg AL, Lanphear JR, Riley BD, et al, &ldquo;Toxic Traveler? Latrodectus Species Envenomation in Michigan With Refractory Symptoms After Antivenin Administration,&rdquo; <i>Clin Toxicol (Phila)</i>, 2009, 47(4):356-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/19274505/pubmed\" target=\"_blank\" id=\"19274505\">19274505</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Handel CC, Izquierdo LA, and Curet LB, &ldquo;Black Widow Spider (<i>Latrodectus mactans</i>) Bite During Pregnancy,&rdquo; <i>West J Med</i>, 1994, 160(3):261-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/8191768/pubmed\" target=\"_blank\" id=\"8191768\">8191768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoover NG and Fortenberry JD, &quot;Use of Antivenin to Treat Priapism After a Black Widow Spider Bite,&quot; <i>Pediatrics</i>, 2004, 114(1):e128-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/15231985/pubmed\" target=\"_blank\" id=\"15231985\">15231985</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isbister GK and Fan HW, &ldquo;Spider Bite,&rdquo; <i>Lancet</i>, 2011, 378(9808):2039-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/21762981/pubmed\" target=\"_blank\" id=\"21762981\">21762981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isbister GK, Brown SG, Miller M, et al, &ldquo;A Randomised Controlled Trial of Intramuscular vs Intravenous Antivenom for latrodectism-the RAVE Study,&rdquo; <i>QJM</i>, 2008, 101(7):557-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/18400776/pubmed\" target=\"_blank\" id=\"18400776\">18400776</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isbister GK, Graudins A, White J, et al, &quot;Antivenom Treatment in Arachnidism,&quot; <i>J Toxicol Clin Toxicol</i>, 2003, 41(3):291-300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/12807312/pubmed\" target=\"_blank\" id=\"12807312\">12807312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monte AA, Bucher-Bartelson B, and Heard KJ, &quot;A US Perspective of Symptomatic <i>Latrodectus spp.</i> Envenomation and Treatment: A National Poison Data System Review,&quot; <i>Ann Pharmacother</i>, 2011, 45(12):1491-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/22116992/pubmed\" target=\"_blank\" id=\"22116992\">22116992</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nordt SP, Clark RF, Lee A, et al, &quot;Examination of Adverse Events Following Black Widow Antivenom Use in California,&quot; <i>Clin Toxicol (Phila)</i>, 2012, 50(1):70-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/22175789/pubmed\" target=\"_blank\" id=\"22175789\">22175789</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Offerman SR, Daubert GP, and Clark RF, &ldquo;The Treatment of Black Widow Spider Envenomation With Antivenin <i>Latrodectus Mactans</i>: A Case Series,&rdquo; <i>Permanente J</i>, 2011, 15(3):76-81.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Malley GF, Dart RC, and Kuffner EF, &quot;Successful Treatment of Latrodectism With Antivenin After 90 Hours,&quot;<i> N Engl J Med</i>, 1999, 340(8):657.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/10049091 /pubmed\" target=\"_blank\" id=\"10049091 \">10049091 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quan D and Ruha AM, &quot;Priapism Associated With <i>Latrodectus mactans</i> Envenomation,&quot; <i>Am J Emerg Med</i>, 2009, 27(6):759, e1-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/19751653/pubmed\" target=\"_blank\" id=\"19751653\">19751653</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rojnuckarin P, &ldquo;Antivenom Skin Test: Theory Versus Practice,&rdquo; <i>Acta Tropica</i>, 2009, 109(1):86.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Russel FE, Marcus P, and Streng JA, &ldquo;Black Widow Spider Envenomation During Pregnancy: Report of a Case,&rdquo; <i>Toxicon</i>, 1979, 17(2):188-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/442109/pubmed\" target=\"_blank\" id=\"442109\">442109</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saucier JR, &ldquo;Arachnid Envenomation,&rdquo; <i>Emerg Med Clin North Am</i>, 2004, 22(2):405-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/15163574/pubmed\" target=\"_blank\" id=\"15163574\">15163574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sherman RP, Groll JM, Gonzalez DI, et al, &ldquo;Black Widow Spider (<i>Latrodectus mactans</i>) Envenomation in a Term Pregnancy,&rdquo; <i>Curr Surg</i>, 2000, 57(4):346-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/11024247/pubmed\" target=\"_blank\" id=\"11024247\">11024247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization, &ldquo;Guidelines for the Clinical Management of Snake Bites in the South-East Asia Region,&rdquo; 2005, World Health Organization, Geneva. Available at  http://www.searo.who.int/LinkFiles/SDE_mgmt_snake-bite.pdf</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12889 Version 85.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045279\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045274\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F24673690\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F136014\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045282\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F136035\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045281\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F136053\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F136018\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298765\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6218053\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F136022\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F136033\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045278\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F136017\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F10180464\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1045286\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12889|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=black-widow-spider-latrodectus-mactans-antivenom-drug-information\" class=\"drug drug_general\">Black widow spider (Latrodectus mactans) antivenom: Drug information</a></li><li><a href=\"topic.htm?path=black-widow-spider-latrodectus-mactans-antivenom-patient-drug-information\" class=\"drug drug_patient\">Black widow spider (Latrodectus mactans) antivenom: Patient drug information</a></li></ul></div></div>","javascript":null}